Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 144

1.

Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma.

Biggi A, Bergesio F, Chauvie S, Bianchi A, Menga M, Fallanca F, Hutchings M, Gregianin M, Meignan M, Gallamini A.

Q J Nucl Med Mol Imaging. 2017 Jul 27. doi: 10.23736/S1824-4785.17.02993-4. [Epub ahead of print]

PMID:
28750493
2.

Doxorubicin effect on myocardial metabolism as a pre-requisite for subsequent development of cardiac toxicity: a translational 18F-FDG PET/CT observation.

Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, Ghidella A, Pomposelli E, Miglino M, Ameri P, Emionite L, Ticconi F, Arboscello E, Buschiazzo A, Massimelli EA, Fiordoro S, Borra A, Cossu V, Bozzano A, Ibatici A, Ponzoni M, Spallarossa P, Gallamini A, Bruzzi P, Sambuceti G, Marini C.

J Nucl Med. 2017 Jun 23. pii: jnumed.117.191122. doi: 10.2967/jnumed.117.191122. [Epub ahead of print]

PMID:
28646013
3.

FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management.

Gallamini A, Borra A.

Mediterr J Hematol Infect Dis. 2017 Apr 15;9(1):e2017029. doi: 10.4084/MJHID.2017.029. eCollection 2017. Review.

4.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
5.

Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.

Gallamini A, Kostakoglu L.

J Nucl Med. 2017 Feb;58(2):196-197. doi: 10.2967/jnumed.116.184663. Epub 2016 Nov 10. No abstract available.

PMID:
28151415
6.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A.

J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.

PMID:
28126883
7.

Response Assessment Criteria and Their Applications in Lymphoma: Part 2.

Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, Nadel H, Kostakoglu L.

J Nucl Med. 2017 Jan;58(1):13-22. doi: 10.2967/jnumed.116.184242. Epub 2016 Nov 22. Review.

PMID:
27879369
8.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
9.

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.

Romano A, Parrinello NL, Vetro C, Tibullo D, Giallongo C, La Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, Di Raimondo F.

Oncotarget. 2016 Oct 11;7(41):67333-67346. doi: 10.18632/oncotarget.12024.

10.

Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.

Tardy MP, Gastaud L, Boscagli A, Peyrade F, Gallamini A, Thyss A.

Hematol Oncol. 2016 Aug 19. doi: 10.1002/hon.2338. [Epub ahead of print]

PMID:
27539158
11.

Clinical presentation and staging of Hodgkin lymphoma.

Gallamini A, Hutchings M, Ramadan S.

Semin Hematol. 2016 Jul;53(3):148-54. doi: 10.1053/j.seminhematol.2016.05.005. Epub 2016 May 13. Review.

PMID:
27496305
12.

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).

Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A.

Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

PMID:
27133138
13.

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.

La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G.

J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4.

14.

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

PMID:
26475305
15.

Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014.

Meignan M, Gallamini A, Haioun C, Barrington S, Itti E, Luminari S, Polliack A.

Leuk Lymphoma. 2015 May;56(5):1229-32. doi: 10.3109/10428194.2015.1029748.

PMID:
26086968
16.

Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?

Gallamini A, Kostakoglu L.

Ann Oncol. 2015 Jun;26(6):1045-7. doi: 10.1093/annonc/mdv160. No abstract available.

PMID:
26003616
17.

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.

Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A.

Haematologica. 2015 Jun;100(6):786-93. doi: 10.3324/haematol.2014.123273. Epub 2015 Mar 6.

18.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

19.

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R.

Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.

PMID:
25650091
20.

FDG PET/CT imaging as a biomarker in lymphoma.

Meignan M, Itti E, Gallamini A, Younes A.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33. doi: 10.1007/s00259-014-2973-6. Epub 2015 Jan 9. Review.

PMID:
25573631

Supplemental Content

Loading ...
Support Center